Patent ID: 11884739
Assignee: ACADEMIA SINICA
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method comprising treating or improving treatment of a patient for a cancer selected from the group consisting of B cell lymphomas, NHL, precursor B cell lymphoblastic leukemia/lymphoma and mature B cell neoplasms, B cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, mantle cell lymphoma (MCL), follicular lymphoma (FL), low-grade, intermediate-grade and high-grade (FL), cutaneous follicle center lymphoma, marginal zone B cell lymphoma, MALT type marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, splenic type marginal zone B cell lymphoma, hairy cell leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, plasmacytoma, plasma cell myeloma, post-transplant lymphoproliferative disorder, Waldenstrom's macroglobulinemia, and anaplastic large-cell lymphoma (ALCL), wherein the patient is in need of such treatment, wherein the method comprises increasing antibody-dependent cellular cytotoxicity (ADCC) activity in the patient by administering to the patient an effective amount of a composition comprising an isolated homogeneous population of anti-CD20 IgG molecules, wherein the anti-CD20 IgG molecules have been glycoengineered and have the same N-glycan on each of the Fc region; wherein:
the N-glycan is free of core fucose;
the N-glycan is
Sia2(α2-6)Gal2 GlcNAc2Man3GlcNAc2,
wherein the glycoengineered anti-CD20 IgG molecules have increased ADCC activity compared to the corresponding monoclonal antibodies that have not been glycoengineered; and
wherein the anti-CD20 IgG molecule comprises a heavy chain having the amino acid sequence set forth in SEQ ID NO: 1, and a light chain having the amino acid sequence set forth in SEQ ID NO: 2 or wherein the anti-CD20 IgG molecule comprises a light chain sequence and a heavy chain sequence of rituximab.